Premier Alternatives

Immunis

Irvine, CA · Founded 2019 · Privately Held (backing)

Developer of stem cell-derived therapy designed to treat age and disease-related immune decline. Immunis is based in Irvine, CA and was founded in 2019. Its last known valuation is $75 million. It has raised $37 million across 2 recorded rounds; the latest was a $12 million early-stage round in May 2026.

Last price · $/share
—
Implied valuation
$75.0M
Total raised
$37.0M
Last round
Early Stage VC
May 2026

Immunis key facts

  • Developer of stem cell-derived therapy designed to treat age and disease-related immune decline.
  • Immunis’s last known valuation is $75.0M.
  • It has raised $37.0M across 2 recorded rounds; the latest was Early Stage VC ($12.0M) in May 2026.
  • Notable investors include BOLD Capital Partners, Elevation Capital (Canada), Angel Star Ventures, Continuum Health Ventures, Fairfax Financial Holdings — 12 tracked in total.
  • Immunis has filed 2 Form Ds with the SEC, most recently Oct 2024 ($20.4M sold to 27 investors).
  • Status: Privately Held (backing).
Free account
More of Immunis with a free account
  • ·The complete investor list: 12 names
  • ·Watch Immunis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Immunis funding rounds

2 rounds
May 2026Early Stage VC$12.0MSEC filing▮
Jun 2024Early Stage VC$20.4MSEC filing▮
Full funding history →

Immunis valuation

Immunis's last known valuation is $75 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How much has Immunis raised?

Immunis has raised $37 million across 2 recorded rounds since 2024. The largest was a $20.4 million early-stage round in Jun 2024; the most recent was a $12 million early-stage round in May 2026.

Immunis has filed 2 Form Ds with the SEC, most recently in Oct 2024 ($20.4 million sold to 27 investors).

Immunis investors

12 investors are on record for Immunis, including BOLD Capital Partners, Elevation Capital (Canada), Angel Star Ventures and Continuum Health Ventures. The early-stage round in May 2026 drew 12 investors.

About Immunis

Developer of stem cell-derived therapy designed to treat age and disease-related immune decline. The company's technology uses human stem cells for clinical use and directs them to become pure populations of defined cells that secrete factors, enabling doctors to treat patients with immune system development, modulation, and health.

Sector
Healthcare
HQ
Irvine, CA, United States
Founded
2019
Employees
19
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$75.0M

Immunis’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.